Wanbury is an API manufacturer based in India. It holds 19 active US drug master files across a filed portfolio of 12 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 14 June 2024 as NAI. Customs aggregates show $57.8M of exports covering 888 molecules to 56 destinations in 2025.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Tanuku, India | 3002980818 |
| Dist-Raigad, India | 3003227148 |
| Molecule | Regulators | Docs |
|---|---|---|
| Metformin | SFDA (Saudi Arabia), US FDA | 7 |
| Diphenhydramine | SFDA (Saudi Arabia), US FDA | 3 |
| Paroxetine | US FDA | 2 |
| Sertraline | US FDA | 2 |
| Dextromethorphan | US FDA | 1 |
| Hydralazine | US FDA | 1 |
| Imiquimod | US FDA | 1 |
| Methoxsalen | US FDA | 1 |
| Quetiapine | US FDA | 1 |
| Rivaroxaban | US FDA | 1 |
| Salsalate | US FDA | 1 |
| Tramadol | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| US FDA | None | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2026 YTD | Not reported | $9.8M | 34 |
| 2025 | Not reported | $57.8M | 56 |
| 2024 | $75.3M | $43.3M | 50 |
| 2023 | $72.7M | $37.9M | 56 |
| 2022 | $73.5M | Not reported | Not reported |
Export figures are customs aggregates. We do not publish the identity of any buyer. Revenue shown in US dollars, converted from the reported currency.
Choose your molecules and target markets. Wanbury comes back tiered against every other supplier able to file there.
Start for free